Episode 37: Regoratinib (FGFR inhibitor) and Atezolizumab in UC with Jonathan Rosenberg

Everything you wanted to know about FGFR inhibition but were afraid to ask.

Related Episodes

Episode 132: Pembro + sEphB4-HAS in bladder cancer
Episode 131: The NORSE Study – Erdafitinib vs Erdafitinib/Cetrelimab
Episode 124: Dean Bajorin – The Uromigos Legends in GU Cancer series
Episode 119: EAU – Surgery in urothelial cancer
Episode 108: Peter O’Donnell gives five year follow-up data on front line pembrolizumab
Episode 107: Neoadjuvant chemo/nivolumab sparing cystectomy
Episode 106: Summary of the three cystectomy sparing neoadjuvant trials at ASCO 2021
Episode 105: A Phase 2 study of novel immune combinations (ICOS) in bladder cancer
Episode 98: Bladder cancer from a patient perspective
Episode 97: Sacituzumab Govitecan